Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences AmBisome (liposomal amphotericin B by Year
AmBisome (liposomal amphotericin B — systemic antifungal) — Rest of World sales ($M) ($M)
Gilead Sciences AmBisome (liposomal amphotericin B: $221M in FY2025, up 4.2% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AmBisome (liposomal amphotericin B — systemic antifungal) — Rest of World sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 221 | +4.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 212 | +12.2% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 189 | +3.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 182 | -19.8% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 227 | +56.6% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 145 | +6.6% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 136 | -6.2% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 145 | +10.7% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 131 | +3.1% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 127 | – | Form 10-K (filed 2019-02-26) ↗ |
Cite this data
StockData. (2026). Gilead Sciences AmBisome (liposomal amphotericin B ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/other-ambisome-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.